Biofrontera Inc. (BFRIW) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Woburn, DE, 미국. 현재 CEO는 Hermann Luebbert.
BFRIW 을(를) 보유 IPO 날짜 2021-10-29, 92 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $349.45K.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
